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Diﬀuse astrocytoma of (WHO grade II) has a tendency to progress spontaneously to anaplastic astrocytoma (WHO grade III)
and/or glioblastoma (WHO grade IV). However, the molecular basis of astrocytoma progression is still poorly understood. In
current study, an essential initial step toward this goal is the establishment of the taxonomy of tumors on the basis of their gene
expression proﬁles. We have used gene expression proﬁling, unsupervised (hierarchal cluster (HCL) and principal component
analysis (PCA)) and supervised (prediction analysis for microarrays (PAM)) learning methods, to demonstrate the presence of
three distinct gene expression signatures of astrocytomas (ACMs), which correspond to diﬀuse or low-grade astrocytoma (WHO
grade II), Anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV). We also demonstrate a 171
gene-based classiﬁer that characterize the distinction between these pathologic/molecular subsets of astrocytomas. These results
further deﬁne molecular subtypes of astrocytomas and may potentially be used to deﬁne potential targets and further reﬁne
stratiﬁcation approaches for therapy. In addition, this study demonstrates that combining gene expression analysis with detailed
annotated pathway and gene ontology (GO) category resources was applied to highly enriched normal and tumor population; it
can yield an understanding of the critical biological mechanism of astrocytomas.
1.Introduction
Astrocytomas (ACMs) are cancers of the brain that origi-
nated in star-shaped brain cells called astrocytes; ACMs ac-
count for roughly 75% of neuroepithelial tumors. Of the
numerous grading systems that have been devised, the most
commonly used system for ACMs is the World Health
Organization (WHO) grading system [1]. The WHO system
assigns a grade from I to IV, with I being the least aggressive
and IV being the most aggressive [2]. The number of col-
lected ACM specimens is relatively low compared with
other tumor collections, and there have been few reports
of in-depth coverage using microarray technology. This
study of ACM gene transcription proﬁles sets the stage for
further discovery of the basic mechanisms that underlie the
diseased state of ACM, which will help to identify targets
for diagnosis and therapeutic intervention. The raw data
has been deposited in the Gene Expression Omnibus (GEO;
http://www.ncbi.nlm.nih.gov/projects/geo/)s ot h a to t h e rr e -
searchers have access to it. Our analysis provides novel
insights into diﬀerencesbetween normal and malignant can-
certissuesthatmaybeusedinassessing theimpactoftherapy
on ACM cells. Because WHO grade I ACM often occurs in
children, this study mainly focused on typically adult-onset
ACM. The independent series of 15 ACMs consisted of ﬁve
samples each of WHO grades II, III, and IV. Incurrent study,
an essential initial step toward this goal is the establishment
of the taxonomy of tumors on the basis of their gene expres-
sion proﬁles. We aimed at identifying expression proﬁles
that diﬀerentiate three groups of astrocytic glioma: WHO
grades II, III, and IV. In a novel gene selection approach, we
combined unsupervised statistical analysis with hierarchical
clustering (HCL) [3], an supervised method called PAM [4]
that applies nearest shrunken centroid analysis to identify
correlated groups of genes that distinguish between the var-
ious tumor subtypes. Here, we demonstrate that ACMs can2 Comparative and Functional Genomics
be separated according to their gene expression proﬁles. By
using expression data of the most informative separating
gene clusters, we were successful to construct an almost per-
fect tumorclustering model. Class predictionwas performed
by using prediction analysis of microarrays for excel pack-
age that applies nearest shrunken centroid analysis [4]t o
determine37predictorgenesthatachieveoptimalprediction
accuracy for sample classiﬁcation. Meanwhile, we have also
applied the gene sets to systems-level pathway analysis and
identiﬁed molecular pathways and networks that are dysreg-
ulated between ACM and normal tissues. To build on this
approach, functional enrichment analysis based on BioCarta
and Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathways [5, 6] can be used to illustrate causal relationships
between genes (gene products). While gene ontology (GO)
[7] is organized into hierarchical annotations in the con-
text of normal cellular function, the BioCarta and KEGG
database organizes genes (gene products) into pathway reac-
tionmapsandfunctionalcomplexes,includingsomedisease-
speciﬁc pathways. Our study provides valuable information
for pharmaceutical screening programs and future cancer
research.
2.Materialsand Methods
The mean age of patients was 48.6 years old (range, 18–
64). Fifteen human pathologic ACM specimens and corre-
sponding normal brain tissue samples were obtained from
resectedtissuesintheNeurosurgeryDepartmentofShanghai
Changzheng Hospital (Shanghai, China) between 2004 and
2006. The normal brain control samples were obtained as
overlying cortex during routine resection of deep inter-
cerebral metastases. All protocols and consent forms were
approved by the hospital’s institutional review board, and
informed consentwas obtained from all patients. The patho-
logical diagnoses of the specimens were conﬁrmed by two
senior clinic-pathological experts, Fulin Zhang and Yichang
Yu, at the Department of Pathology, Huashan Hospital, Fu
Dan University (Shanghai, China) before RNA extraction
was performed. Specimens were snap frozen in liquid nitro-
gen and stored at −80◦C. Histological characteristics of tu-
mor samples and clinical disease stage, ﬁve WHO grade
II, III, and IV ACMs and one pooled and three additional
normals, are shown in Table 1.
RNA was extracted using Trizol reagent and further
puriﬁed using the Qiagen RNeasy Mini Kit according to the
manufacturer’s instructions. RNA quality was assessed by
formaldehyde agarose gel electrophoresis and was quantiﬁed
by spectrophotometry. The samples were hybridized to the
Aﬀymetrix Human Genome U133 Plus2.0 GeneChip arrays
according to the Aﬀymetrix protocols. The arrays were
scanned with a GeneChip Scanner 3000. The scanned array
images were processed with GeneChip Operating software
(GCOSv1.3), and the CEL ﬁles were extracted for further
analysis. The raw data were deposited in the Gene Expres-
sion Omnibus (GEO, http://www.ncbi.nlm.nih.gov/projects/
geo/) with accession series number GSE19728, consisting of
17 diﬀerent grades tumor samples plus four normal brain
tissue sample, and GSE21354including three additional nor-
malbraintissue specimens theGEOsample names havebeen
shown in Table 1.
The CEL ﬁles from all datasets (newly generated array
data from 15 ACMs, including 5 WHO II, 5 III, and 5 IV
and unmatched pooled normal and 3 additional normal
samples) were imported into the statistical software R
(v2.10.1.) [8] using Bioconductor (v2.5.11) [9]. After pre-
installing two key packages, hgu133plus2cdf (v.2.5.0) and
hgu133plus2probe (v.2.5.0), in R environments, the quality
control of Aﬀymetrix arrays (Aﬀymetrix Hu133plus2.0) was
ﬁrst performed using the package aﬀy (v 1.24.2) and sim-
pleaffy (v 2.22.0) for Raw CEL ﬁles. RNA degradation was
assessed using the function AﬀyRNAdeg() from the aﬀy
package. We checked the results of quality control imple-
mentation; all the qualities of arrays were pretty satisﬁed (see
SupplementaryFigure 1inSupplementaryMaterialavailable
online at doi: 10.1155/2011/245137), then the raw data were
normalized using the package gcRMA [10]. We used the
“aﬃnities” model of gcRMA, which uses mismatch probes as
negative control probes to estimate the nonspeciﬁc binding
of probe sequences. The normalized values of expression are
in log2 scale, which attenuates the eﬀect of outliers. The
presence/absence calls provide a statistical measure of the
presence of a transcript within the tested biological sample.
Details of the calculations can be found in the Aﬀymetrix
Microarray Suite UserGuide [11]. For the absolute detection
of transcripts (presence or absence calls), the method we
used [12] replaces all MM probe values by a threshold value
which isbasedonthemean PMvalue(aftergcRMAtransfor-
mation) ofprobesetsthatare verylikelytohaveabsenttarget
transcripts. This removes the inﬂuence of probe sequence
aﬃnity and results in better performance than the MAS 5
algorithm [13]. In current study, the command mas5calls()
of Bioconductor was used to generate MAS 5.0 P/M/A
calls. Of the resulting output only the presence/absence calls
were extracted and then mapped to the expression values
output from the gcRMA [14]. We then saved the normalized
expression values with the corresponding P/M/A values in
a matrix. This matrix was regarded as data source in TIGR
MeV Version 4-6-01 software tool (http://www.tm4.org/)
[15]. For ﬁlter in MeV operation platform, (a) we ﬁrst
removedasetofprobesthatwereusedforqualitycontrol;(b)
a matrix was composed of each probe ID, expression value,
and its corresponding sample CALL (CALL: P,p r e s e n t ;A,
absent, M, medium); thefollowing formula was used to ﬁlter
the redundant probes,
value =
N(P)
N(P) + N(A) + N(M)
× 100%, (1)
where N(P), N(A), N(M)s t a n df o rt h en u m b e ro fP, A, M,
respectively; if the value ≤10%, the corresponding probe ID
would be excluded.Brieﬂy,theprobe with P/(P+M+A)% ≤
10 was removed.
Analysis of variance (ANOVA) [16]i sat e c h n i q u et h a t
assesses whether a set of measurements from two or more
experimental groups indicates, given observed variance, that
t h eg r o u p sa r ed i ﬀerent. For microarrays the measurements
are the expression levels of one transcript, and the groupsComparative and Functional Genomics 3
Table 1: Patients’ characteristics.
No Array ID GEO No Title Histologicaldiagnosis Age/Gender WHO grade
1 190-063A GSM492652 Astrocytomas T2-1-Signal Diﬀuse or low-grade astrocytoma 72, M II
2 0286-29 GSM492653 Astrocytomas T2-2-Signal Diﬀuse or low-grade astrocytoma 32, M II
3 0286-71 GSM492654 Astrocytomas T2-3-Signal Diﬀuse or low-grade astrocytoma 73, M II
4 0286-98 GSM492655 Astrocytomas T2-4-Signal Diﬀuse or low-grade astrocytoma 45, M II
5 0286-86 GSM492656 Astrocytomas T2-5-Signal Diﬀuse or low-grade astrocytoma 65, M II
6 0286-94 GSM492657 Astrocytomas T3-1-Signal Anaplastic astrocytoma 18, F III
7 0286-95 GSM492658 Astrocytomas T3-2-Signal Anaplastic astrocytoma 64, F III
8 0190-068 GSM492659 Astrocytomas T3-3-Signal Anaplastic astrocytoma 28, M III
9 0286-27 GSM492660 Astrocytomas T3-4-Signal Anaplastic astrocytoma 45, M III
10 0286-88 GSM492661 Astrocytomas T3-5-Signal Anaplastic astrocytoma 54, M III
11 0190-031B GSM492662 Astrocytomas T4-1-Signal Glioblastoma multiforme (GBM) 68, M IV
12 0286-83 GSM492663 Astrocytomas T4-2-Signal Glioblastoma multiforme (GBM) 62, M IV
13 0286-89 GSM492664 Astrocytomas T4-3-Signal Glioblastoma multiforme (GBM) 80, M IV
14 0286-92 GSM492665 Astrocytomas T4-4-Signal Glioblastoma multiforme (GBM) 78, F IV
15 0286-90 GSM492666 Astrocytomas T4-5-Signal Glioblastoma multiforme (GBM) 69, M IV
16 Normal Plus1 GSM525014 Normal Normalbrain tissues Normal
17 Normal Plus2 GSM525015 Normal Normalbrain tissues Normal
18 Normal Plus3 GSM525016 Normal Normalbrain tissues Normal
19 0190-normalA GSM492649 Normal Pooled normaltissues Normal
correspond to the experimental sample groups. The most
basic type of ANOVA is a one-way ANOVA. In a one-way
ANOVA, the sample groups are stratiﬁed along a single
experimental variable. Currently, only one-way ANOVA is
implemented in TIGR MeV (V 4-6-01) software tool. The
user is initially required to enter the number of groups in
our study, the numbers are set to 4 (ACMs II, III, IV, and
normals). We then ﬁt one-way ANOVAmodels with separate
means for each of the four groups. Standard Bonferroni
correction is calculated for each gene, and a gene is con-
sidered signiﬁcant if P value associated with its Standard
Bonferroni correction is smaller than the critical P value
(0.01). Currently, P values are computed only from the
Standard Bonferroni correction. We performed standard
Bonferroni correction for each of the null hypotheses that
the means of the average intensities of the four groups
were equal; the alternative hypothesis was that at least one
mean was diﬀerent. After one-way ANOVA processing, the
signiﬁcance probe sets (saved as new original data source)
were performed by HCL in TIGR MeV software tool and
principal components analysis (PCA) [17]u s i n gt h eR
function prcomp (...,s c a l e=TRUE) of Bioconductorversion
2.2. HCL was performed using the Euclidean distance and
the average linkage algorithm.
For all kinds of data mining algorithms, we performed
unsupervised data mining including HCL; on the other
hand, for the supervised mining method, we chose predic-
tion analysis of microarrays (PAM) [4] for class predication
of all samples. The ﬁltered dataset was separated in learning
dataset including two normal samples, three WHO grade II,
III, and IV ACMs, and test datasets consisting of two normal
samples, two WHO grade II, III and IV ACMs using 10-
fold cross-validation. One-way ANOVA was implemented
to deﬁne the signiﬁcant probes in TIGR MeV (V 4-6-01)
software tool all the parameter settings and performances
referred to the preceding descriptions. Class prediction with
10-foldcrossvalidationusingPAMforexcelpackagewasper-
formed for the 996 signiﬁcant probes exported from TIGR
MeV. (http://www-stat.stanford.edu/∼tibs/PAM/)( v e r s i o n
2.212) [4]. In PAM operation, with threshold (Δ) of 41.0,
we built a classiﬁer containing 171 probes which gave “zero”
misclassiﬁcation error (refer to Supplementary Figure 2);
the classiﬁer generated was applied to the test data which
is matrix data consisting of aforementioned 996 signiﬁcant
probes and corresponding expression values in the test
datasets.
The diﬀerentially expressed genes (DEGs) output from
one-way ANOVA performance. All DEGs were ﬁrst distrib-
uted for functional proﬁles using Gene Ontology terms
includingbiologicalprocess,cellularcomponent,and molec-
ular function (http://david.abcc.ncifcrf.gov/)[ 18], with hy-
pergeometric distribution [19] and FDR correction param-
eter settings [20]. The three category-annotated ﬁles con-
taining the gene annotations and categories of biological
process, cellular component, and molecular function, were
exported using DAVID online tools [20]. In each ﬁle, the
GO terms in each annotated categorywith corrected P values
(expanded) <0.05 were collected. Unannotated genes were
excluded. The GO database was updated as of July 1st, 2009.
Two databases, BioCarta and KEGG, were used to identify4 Comparative and Functional Genomics
signiﬁcantly altered pathways. Dys-regulated pathways were
identiﬁed using the DAVID system [18, 21]b ym e a n so f
mapping the DEGs generated by one-way ANOVA into the
BioCarta and KEGG databases. A P value for each pathway
was obtained using the hypergeometric test described by
Zhang et al. [22].
3.Results
We analyzed the expression of 54,676 probe IDs using
Aﬀymetrix HU-133PLUS 2.0 GeneChip microarrays for 15
ACM tissue samples consisting of ﬁve each of grade II,
III, and IV tumors and four normal tissue specimens. The
quality control was implemented for the raw data after
normalization. Basic quality control for Aﬀymetrix array
consists of checking for RNAdegradation and examining the
expression for control genes, scaling factors, percentage of
present genes, and the average background. Supplementary
Figures 1(a) and 1(b) show the general quality control
statistics and RNA degradation of all arrays; the information
in Supplementary Figure 1 explicitly illustrates that the
quality of all those arrays is completely acceptable.
3.1. HCL and PCA. After gcRMA normalization and ﬁlters,
the remaining 32,095 probes were performed using one-
way ANOVA, and then the 4015 probes left were executed
by PCA, HCL, and class prediction (see Methods and
Materials). The dendrogram and heatmap (Figures 1(a) and
1(b), resp.) from hierarchal clustering and two (2D plot
Figure 1(c)) and three (3D plot Figure 1(d)) main principal
components from PCA analysis illustrate that ACMs and
normal tissue samples can be almost perfectly separated
according to their pathological stages.
We used a HCL and PCA algorithm to study the changes
in the ACMs on a genome-wide level. The resultant data
are shown in Figure 1.I nF i g u r e1(b), each row represents
the expression levels of a particular gene across all samples,
and each column represents the expression level of all of the
genes tested for each sample. At a glance, our genome-wide
level analysis showed that the ACM samples were grouped
into one cluster, whereas the normal control samples were
clusteredseparately. This shows that genome-wide transcript
proﬁling can be used to distinguish ACM from normal
tissue. Furthermore, within the cancer cluster, tumors from
a particular pathologic grade or clinical stage were also
clustered reliably with other tumors of the same grade or
stage, indicating that there is signiﬁcant molecular proﬁle
among tumors classiﬁed within a particular pathologic
grade or clinical stage (Figures 1(a) and 1(b)). The tumor-
tissue cluster consists of two subbranches, one is only
WHO grade II cluster and another includes WHO III
and WHO IV clusters. Multidimensional scaling using the
ﬁrst two (Figure 1(c)) and three (Figure 1(d))p r i n c i p a l
components, a linear projection method that reduces the
complex dimensionality of microarray data to create a
three-dimensional plot that visualizes the relatedness of the
tumors, was then used to test whether the above subsets
could be used to distinguish WHO II, III, and IV tumor and
normal brain. This analysis showed a clear separation of all
three groups based on these genes. In general, the analysis
of HCL and PCA (Figure 1) explicitly indicates that classi-
ﬁcation of ACM on the basis of genome-wide level is com-
pletely consistent with clinical stages, which is an inspiring
result.
3.2. ACM Classiﬁcation. We applied a supervised analysis
using “nearest shrunken centroid classiﬁer” and the PAM for
excel package (version 2.212). As Supplementary Figure 2
shows, the threshold (Δ) of 41.0 was chosen as arguments,
we built a classiﬁer containing 171 genes which gave mis-
classiﬁcation error = 0 (Supplementary Figure 2). We then
used this classiﬁer to predict the subtypes of the 6 tumors
and 2 normal samples analyzed in this study. As Table 2 and
Figure 2 show, the results of predication are in agreement
with clinical pathological classiﬁcation. In order to gain the
marker genes of diﬀerent pathological grade of ACM, we
further run listgenes button with threshold = 41.0 in PAM for
excel package. As a result, 12 genes for grade II, 12 genes for
grade III, and 13 genes for grade IV (Table 3) were selected
as markers to distinguish diﬀerent grade pathological tis-
sues, excluding the 132 genes referred to as normal tissue
markers.
3.3. GO Categories. Similarly, after gcRMA normalization
and ﬁltering and one-way ANOVA procedures, the 4015
probes left were mapped to 2649 unique gene symbols,
and those genes were further analyzed using DAVID system
(parameter settings, refer to Methods and Materials) (http://
david.abcc.ncifcrf.gov/). The signiﬁcantly overrepresented
GO terms (corrected P values<0.5 and no gene>10) are
shown in Supplementary Table 1. In the cellular component
category, 19 GO terms were signiﬁcant, including extrinsic
to membrane, endomembrane system, cell junction, nuclear
lumen, chromatin remodeling complex, integral to organelle
membrane, intrinsic to organelle membrane, and plasma
membrane part. Most of these were enriched in the “core
dataset” membrane at the same signiﬁcance level. In the
molecularfunction category,17 GO termswere enriched, in-
cluding enzyme binding, metal ion binding, zinc ion bind-
ing, cation binding, Ras GTPase binding, transition metal
ion binding. The predominant terms related to biological
processesconsistedofintracellularsignalingcascade,positive
regulation of apoptosis, and positive regulation of program-
med cell death.
3.4. Dysregulated Pathways. The signiﬁcance of enrichment
fromone-wayANOVAimplementationwascalculatedbythe
hypergeometric test with microarray type Aﬀymetrix HU-
U133-PLUS-2.19 dysregulated pathwayswith more than ﬁve
DEGs and with P< 0.01 in Biocarta database and in the
KEGG data base were identiﬁed using DAVID (Supplemen-
tary Table 2). The ﬁve most signiﬁcant BioCarta pathways
were ﬁrst multivalent nuclear factor, FAS signaling pathway
(CD95), p38 MAPK signaling pathway, control of skeletal
myogenesis by HDAC and calcium/calmodulin-dependent
kinase (CaMK), role of BRCA1, BRCA2, and ATR in cancerComparative and Functional Genomics 5
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Figure 1: The exhibition of results of HCL and PCA. Hierarchal clustering: the analysiswas performed using the Euclidean distance and the
averagelinkagealgorithm;principalcomponentanalysiswithscaling.(a)dendrogramplot:theastrocytomastissuegroupandnormal-tissue
group were separated obviously in the top node; tumor node is composed of two branches, one is just WHO II grade, and another includes
WHO III cluster and WHO IV cluster; (b) heatmap plot: each column represents the expression levels for all genes in a particular sample,
whereas each row represents therelative expression of a particular gene acrossall samples.The expression level of anygiven gene in anygiven
sample (relative to the mean expression level of that gene across all tissue samples) is reported along a color scale in which red represents
transcriptional upregulation, green represents downregulation, and the color intensity indicates the magnitude of deviation from the mean;
(c) the two main principal components2D-plot; (d) the three mainprincipal components3D-plot. In Figures 1(c) and1(d):d iﬀerent colors
stand for diﬀerent pathological stages, Green, blue, yellow, and red represent normal, II, III, and IV grade, respectively.6 Comparative and Functional Genomics
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Figure 2: Estimated probabilities forthecross-validation(a)andtest data (b).Samplesare partitioned by the true class(a)andthepredicted
class (b). All 11 of the training samples and all 8 of the test samples knownto be astrocytomas are correctly classiﬁed.
Table 2: Actual and predicted classiﬁcation.
Sample labels Normal plus2 Normal plus3 II-86 II-98 III-84 III-95 IV-90 IV-92
Predicted class
labels Normal Normal Stage-2 Stage-2 Stage-3 Stage-3 Stage-4 Stage-4
N o r m a l 11000000
S t a g e - 2 00110000
S t a g e - 3 00001100
S t a g e - 4 00000011
susceptibility. The top ﬁve signiﬁcant dysregulated path-
ways from the KEGG database were pathways in cancer,
mitogen-activated protein kinase (MAPK) signaling pathway
(Figure3),inositolphosphatemetabolism,dilatedcardiomy-
opathy, focal adhesion, calcium signaling pathway.
4.Discussion
Although microarray technology is now available to many
researchers, methods for evaluation and interpretation of
microarray data are still evolving. To date, most microarray
studies presented from clinical settings concentrated on
classiﬁcation and/or pattern recognition for discrimination
among diﬀerent tumor types or subgroups. Here, we gener-
ated expression proﬁles of 15 tumors using HG-U133plus2.0
chips (Aﬀymetrix) to characterize the astrocytomas tran-
scriptome comprising the clinical stages. We focused on
molecular deﬁnition of clinical and biological subgroups
and the identiﬁcation of molecular transcription-level gene
signatures of astrocytomas.
We used a HCL and PCA algorithm to study the changes
in gene expression in the ACMs on a genome-wide level.
Consequently, our analysis showed a clear separation of all
three groups based on these genes, which suggest that there
are classable diﬀerences underlying transcriptional level of
genes amongst tissue-type categorization of astrocytomas.
Fortunately,we are successful to classify accuratelythe ACMs
into three subgroups, WHO II, III, IV, by PAM method and
detect the marker genes aiming at the diﬀerent pathological
stages of ACM (Table 3). It is interesting to compare our
list of 37 genes with genes that are presently considered to
be diagnostic for ACMs. In the future research, several gene
products will be measured by immunostaining and PCR
to distinguish he ACMs from each other: 12 upregulated
genes including gene C12orf39 are speciﬁc for WHO II; 8
upregulated genes and 4 downregulated genes are speciﬁc
for WHO III, and 13 upregulated genes are speciﬁc for
WHO IV. The data are displayed in Table 3 to demonstrate
their shortcomings in comparison to the genes identiﬁed by
nearest shrunken centroids.
We further analyzed the gene expression proﬁling of
ACMs using GO category and pathway using Biocarta and
KEGG database. The dys-regulated pathways and GO terms
implicated in ACMs were reported. In the dys-regulated
pathwaysimplicatedinACM,inositolphosphatemetabolismComparative and Functional Genomics 7
Table 3: The marker genes of three diﬀerent grades of ACM.
Gene symbol II-astro score III-astro
score IV-astro score Normal-score II-mean
(log base 2)
III-mean
(log base 2)
IV-mean
(log base 2)
Normalmean
(log base 2)
EPHB1 15.4462 0 0 0 6.869894 2.55495 2.65409 2.72811
LOC732229 13.8658 0 0 0 5.460512 2.59371 2.77408 2.26366
C12orf39 8.5766 0 0 0 5.361751 2.238085 2.58682 2.48695
MARVELD3 7.8886 0 0 0 6.800398 2.37729 2.86839 2.39552
LOC283677 4.4758 0 0 0 3.883122 2.826663 2.71392 2.8898
C20orf42 3.5577 0 0 0 7.627308 2.859789 2.4558 2.52664
SPTLC3 3.2679 0 0 0 4.01698 2.255256 2.30132 2.59188
KCNQ1OT1 2.9128 0 0 0 4.103731 2.338234 2.2464 2.26363
FLJ21062 2.1167 0 0 0 4.753168 2.238085 2.48495 2.26875
ATP13A5 1.9707 0 0 0 3.214755 2.238085 2.2464 2.43345
PDXDC1 1.3847 0 0 0 3.134729 2.25661 2.26636 2.26363
CNNM2 0.8081 0 0 0 3.148803 2.27347 2.6133 2.54342
ZBTB39 0 15.0318 0 0 4.173501 6.19055 4.6856 4.68794
C6orf89 0 11.2219 0 0 2.621672 4.699428 2.91788 2.30613
LOC116236 0 11.0126 0 0 2.254329 4.397317 2.72612 2.44326
FKHL18 0 10.2107 0 0 2.258635 3.994112 2.2464 2.6121
CTRL 0 10.0666 0 0 2.526428 3.937424 2.31851 2.58541
TIRAP 0 9.5523 0 0 2.324936 4.216794 2.2464 2.75954
NEUROG1 0 2.5236 0 0 2.258056 3.768388 2.64751 2.27475
TMEM44 0 0.4603 0 0 2.315798 3.374982 2.45605 2.51802
RPUSD1 0 −0.647 0 0 4.034009 2.703442 3.84208 4.14466
DHRS7 0 −2.0711 0 0 3.425335 2.573317 3.60534 4.03533
AKAP7 0 −2.6126 0 0 4.723465 2.652648 5.11056 3.7332
PDE3B 0 −4.2169 0 0 5.989233 4.535432 6.10718 6.31594
C20orf160 0 0 14.9825 0 2.523126 2.790445 4.41487 2.27477
PKMYT1 0 0 11.89 0 2.644079 2.486864 3.84824 2.26751
TRPV2 0 0 10.5089 0 2.397686 2.732524 4.5048 3.31894
LEFTY2 0 0 5.3507 0 2.231583 2.258491 5.56688 2.28191
C20orf77 0 0 5.1848 0 2.333998 2.404051 3.48131 2.3379
MOBKL2C 0 0 3.8936 0 2.517987 2.58549 3.86723 2.45653
STAC 0 0 2.9965 0 2.275399 2.238151 6.32448 2.78522
GGA3 0 0 2.8351 0 2.295872 2.433914 3.46887 2.26651
VAV1 0 0 2.1584 0 2.396392 2.515654 4.53627 2.34353
TXNRD2 0 0 1.3886 0 2.582906 2.358745 3.38602 2.41848
SP100 0 0 0.9134 0 2.385938 2.339246 3.58699 2.37374
LCP2 0 0 0.7656 0 2.268675 2.292975 3.62601 2.88405
RHEB 0 0 0.6002 0 2.254732 2.244571 3.16583 2.31595
The ﬁrst column lists the marker genes for diﬀerent ACM WHO grades; the scores from 2th to 5th columns suggest the estimates of the class probabilities by
PAM [4], which are similar to that used in linear discriminant analysis(LDA); the means from 6th to 9th columns represent the average values of log (base 2)
gene expression. Bold indicates a marker gene of one WHO grade ACM relative to other WHO grades which are overexpressional; italic indicates those that
are underexpressional.
was reported to be involved in astrocytomas [23]. Wang
et al. [24] demonstrated that p125 focal adhesion kinase
(p125FAK) is a cytoplasmic tyrosine kinase that is activated
upon engagement of integrin cell adhesion receptors and
initiates several signaling events that modulate cell function
in vitro [24]. A recent report suggested that the communica-
tion pathway has received utmost attention since it is known
that astrocytic calcium signals can be induced by neuronal
stimulation and can be communicated back to the neurons
to modulate synaptic transmission [25]T h ec u r r e n ts t u d y8 Comparative and Functional Genomics
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Figure 3: MAPK signalingpathway. Red stars marks indicate dysregulated genes.
represents the ﬁrst eﬀort to simultaneously compare the
transcriptional proﬁlesofhighly enriched ACMsand normal
tissues from a variety of patients using modern microarray
technology. The comparison of expression patterns of ACM
and normal tissues enhanced our ability to identify genes
and pathways that are disrupted in ACM tumor tissue. This
analysisprovidescriticalinsightsintothediﬀerencesbetween
normal and malignant cancer tissue populations that may be
used for assessing therapies targeting ACM.
Analysis of speciﬁc cellular processes and pathways with-
in the diﬀerenttransgenerationally altered gene sets is shown
in Supplementary Table 2. The pathways containing the
highest numbers of aﬀected genes are listed. The mitogen-
activated protein kinase (MAPK) signaling pathway was
aﬀected in all of the altered gene sets (Figure 2). MAPK sig-
naling is responsive to a large number of regulatory factors
[26]; MAPK signaling pathways are evolutionarily conserved
in eukaryotes and are involved in many cellular processes,
including growth, diﬀerentiation, apoptosis, and the im-
mune response [27]. These pathwaysfeature a conserved sig-
naling cascade downstream of small GTPases of the Ras and
Rho families. The cascade consists of a MAPK kinase kinase
kinase, which phosphorylates and activates a MAPK kinase
kinase, which then activates the MAPK by phosphorylation
o nT h ra n dT y rr e s i d u e sw i t h i nac o n s e r v e dm o t i fl o c a t e d
in the kinase activation loop [27]. A considerable number
of studies have demonstrated the dysregulation of MAPK
signaling in a variety of cancers [28]. For example, Bakin
et al. [29] showed that MAP kinase activation correlates with
the progression to advanced hormone refractory disease in
patient samples and that stable expression of Ras eﬀector
loop mutants that activate the Ras/MAP kinase pathway is
suﬃcient to reduce the androgen requirement of LNCaP
prostate cancer cells for growth, prostate-speciﬁc antigen
expression, and tumorigenicity [29]. A recent report by
Zafon and Obiols [30] showed that constitutive activation
of the MAPK signaling pathway is a major event in the pro-
gression of papillary thyroid carcinoma [30]. Mizoguchi
et al. [31] found that MAPK signaling was correlated with
malignant astrocytic gliomas[31]. The results ofour analysis
suggest that this pathway is dysregulated in ACM and may
contribute to the pathogenesis of ACM.
5.Conclusion
There are an abundance of data on the gene expression pro-
ﬁles of normal and ACM tissue. A few studies have recentlyComparative and Functional Genomics 9
been published that aimed to detect molecular markers to
distinguish the diﬀerent grade ACMs. In our study, the
method of nearest shrunken centroids was successful in
ﬁnding genes that accurately predict classes. The method
found a set of 37 genes that was able to assign ACMs to
one of three classes, WHO II, III, and IV ACMs, with 100%
accuracy. The success of our methodology has implications
forimproving thediagnosisofcancer.The methodeﬃciently
ﬁnds and ranks genes that can distinguish one type of tumor
from another. Ultimately, it may be used to search for genes
that are predictive for response to chemotherapy. For ACMs,
the predictive genes are attractive candidates for raising anti-
bodies suitableforimmunostaining. Immunohistochemistry
has an advantage for analyzing diﬃcult specimens, because
it allows the pathologist to localize the stain to tumor cells.
In addition, our results suggest that RNA-based diagnostic
tests may soon become feasible, based on either small-scale
microarrays or quantitative PCR.
Inaddition, weperformed clusteringandclassiﬁcationof
GOcategoriesanddysregulatedpathwaysonthebasisofgene
expression in ACM versus normal brain tissue. According
to the microarray-wide gene level, we ﬁrst reported that
categorization ofACMsby gene expression using HCL, PCA,
and PAM is almost completely in agreement with clinical
pathological stages. This study sets the stage for the further
discovery of basic mechanisms that underlie a diseased state
of astrocytoma and will be useful in targeting genes for
diagnosis and therapeutic intervention.
Comparing the expression signatures of ACM from dif-
ferent grades (II, III, and IV) of ACM patients to that of
normal tissue, we identiﬁed the DEGs of ACMs, on the basis
of which, GO terms and dysregulated pathways implicated in
astrocytomas have been identiﬁed and proﬁled. Supplemen-
tary Table 2 summarizes the top dysregulated pathways by
P value from the KEGG and BioCarta databases and shows
the number of genes referenced by the KEGG and Biocarta
pathways and the numbers of genes that were found in
our data set by one-way ANOVA analysis. For each KEGG
or Biocarta pathway, an unbiased systems-level pathway
analysis was implemented by DAVID. The P value of each
pathway reﬂects the signiﬁcance of pathway dysregulation.
These pathways, such as MAPK signaling, were identiﬁed
as signiﬁcant. The DEGs were eﬀectively categorized by GO
terms between ACM and normal tissue samples.
The use of pathway analysis and GO categories to derive
gene signature networks has several advantages. First, it
allows a transition from biological function at the molecular
level to a more global, systems approach to disease and
biological processes. Second, it identiﬁes key regulators and
transcription factors thatmightnotbeidentiﬁedby microar-
ray technologyalone. Third, it permitsfurther interpretation
ofgeneexpressiondatabyprovidinginformationonprotein-
protein interactions, metabolic, signaling, and transcription
regulatory networks. This paper thus provides a novel global
view of the diﬀerences between ACMs and normal tissue at
thetranscriptional level.Furtherinvestigationand validation
by experiments should be targeted to the processes that have
been identiﬁed to play key roles in metabolic and signaling
pathways in ACM. The raw data has been deposited in GEO
(http://www.ncbi.nlm.nih.gov/projects/geo/)s ot h a to t h e r
researchers can have access to this important resource.
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